Society Logo
ME/CFS Australia Ltd
Please Click Here To Donate ME/CFS Australia (SA) Inc
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm
Closed over Christmas
(reopened 1 February 2017)

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

Health Care Use Remains High in Patients With Fibromyalgia After Treatment

Monday 16 February 2015

 

From Healio Rheumatology:

 

Healio
 

Health care use remains high in patients with FM after treatment

By Shirley Pulawski
February 13, 2015

Kim SC, et al. Arthritis Res Ther. 2015;doi:10.1186/s13075-015-0530-8.

Utilization of the health care system remained high for patients with fibromyalgia after initiating treatment with either amitriptyline, Cymbalta, Neurontin or Lyrica, according to researchers from Brigham and Women’s Hospital.

Claims data were studied to identify 116,183 patients with one or more diagnoses of fibromyalgia (FM) between Jan. 1, 2007, and Dec. 31, 2009, using ICD-9 codes. Eligible patients were older than 18 years of age and had been enrolled with the insurer for at least 180 days before initiation of four treatment drugs included in the study.

Patients taking amitriptyline, Cymbalta (duloxetine, Eli Lilly), Neurontin (gabapentin, Pfizer) or Lyrica (pregabalin, Pfizer) were matched with patients prescribed pregabalin to compare outcomes of health care utilization. The researchers identified 13,404 patients prescribed amitriptyline, 18,420 prescribed duloxetine, 23,268 prescribed gabapentin and 19,286 prescribed pregabalin. Among those patients, 8,269 patients taking amitriptyline, 9,941 taking duloxetine and 18,613 taking gabapentin were matched with patients taking pregabalin on their propensity score at a 1:1 ratio.

Baseline factors were adjusted for health care utilization factors, and the researchers used multivariate Cox models to estimate rate ratios for emergency department (ED) visits, acute care hospitalization and physical therapy during follow-up. Multivariate Poisson regression was used to estimate rate ratios for outpatient visits to any physician, primary-care physicians, specialists and the number of prescribed drugs during follow-up among each of the three propensity score-matched pairs.

Throughout the 180-day baseline period, the frequency of health care utilization and the number of prescribed drugs were high, according to the researchers, with an average of seven to nine physician visits and receipt of eight prescriptions.

The number of outpatient visits, more than one hospitalization and prescriptions decreased slightly after treatment, but the proportion of patients with more than one ED or physical therapy visit increased in all groups.

In multivariate Cox and Poisson regression, fewer outpatient visits were seen in patients prescribed duloxetine compared to the pregabalin group. In the amitriptyline group, a significantly lower rate of hospitalization was seen. The researchers found few differences were seen between the gabapentin and pregabalin groups. – by Shirley Pulawski

Disclosure: Kim is supported by the NIH grant K23 AR059677. She received a research grant from Pfizer. Please see the full study for a list of all other authors’ relevant financial disclosures.

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


 

blog comments powered by Disqus
Previous Previous Page